Dapiprazole
Dapiprazole (Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination.[1]
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a601043 |
| Pregnancy category |
|
| Routes of administration | Topical (eye drops) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Negligible when administered topically |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H27N5 |
| Molar mass | 325.460 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
References
- Doughty MJ, Lyle WM (May 1992). "A review of the clinical pharmacokinetics of pilocarpine, moxisylyte (thymoxamine), and dapiprazole in the reversal of diagnostic pupillary dilation". Optometry and Vision Science. 69 (5): 358–68. doi:10.1097/00006324-199205000-00005. PMID 1350669. S2CID 22781280.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.